| Year |
Citation |
Score |
| 2013 |
Christoph S, Deryckere D, Schlegel J, Frazer JK, Batchelor LA, Trakhimets AY, Sather S, Hunter DM, Cummings CT, Liu J, Yang C, Kireev D, Simpson C, Norris-Drouin J, Hull-Ryde EA, et al. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Molecular Cancer Therapeutics. 12: 2367-77. PMID 23997116 DOI: 10.1158/1535-7163.Mct-13-0040 |
0.749 |
|
| 2013 |
Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt SG, Kuan PF, Hamilton RL, Duncan LM, Miller CR, et al. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. The Journal of Clinical Investigation. 123: 2257-67. PMID 23585477 DOI: 10.1172/Jci67816 |
0.688 |
|
| 2013 |
Lee-Sherick AB, Eisenman KM, Sather S, McGranahan A, Armistead PM, McGary CS, Hunsucker SA, Schlegel J, Martinson H, Cannon C, Keating AK, Earp HS, Liang X, DeRyckere D, Graham DK. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene. 32: 5359-68. PMID 23474756 DOI: 10.1038/Onc.2013.40 |
0.706 |
|
| 2013 |
Brandao LN, Winges A, Christoph S, Sather S, Migdall-Wilson J, Schlegel J, McGranahan A, Gao D, Liang X, Deryckere D, Graham DK. Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia. Blood Cancer Journal. 3: e101. PMID 23353780 DOI: 10.1038/Bcj.2012.46 |
0.639 |
|
| 2013 |
Christoph S, Schlegel J, Alvarez-Calderon F, Kim YM, Brandao LN, DeRyckere D, Graham DK. Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission. Journal of Hematology & Oncology. 6: 10. PMID 23343252 DOI: 10.1186/1756-8722-6-10 |
0.624 |
|
| 2012 |
Migdall-Wilson J, Bates C, Schlegel J, Brandão L, Linger RM, DeRyckere D, Graham DK. Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus. Plos One. 7: e31635. PMID 22363695 DOI: 10.1371/Journal.Pone.0031635 |
0.628 |
|
| 2012 |
Christoph S, DeRyckere D, Schlegel J, Sather S, McGranahan A, Franzer JK, Trakhimets A, Wang X, Kireev D, Janzen W, Liu J, Yang C, Simpson C, Norris-Drouin J, Frye S, et al. Evaluation of UNC569, a Novel Small Molecule Mer Inhibitor for the Treatment of ALL in Vitro and in Vivo. Blood. 120: 2607-2607. DOI: 10.1182/Blood.V120.21.2607.2607 |
0.663 |
|
| 2012 |
Lee-Sherick AB, Menachof K, Eisenman KM, McGranahan A, McGary C, Hunsucker SA, Schlegel J, Armistead PM, Liang X, Kireev D, Janzen W, Liu J, Stashko M, Norris-Drouin J, Earp HS, et al. Mer Receptor Tyrosine Kinase Is A Potential Therapeutic Target in Acute Myeloid Leukemia Blood. 120: 1317-1317. DOI: 10.1182/Blood.V120.21.1317.1317 |
0.716 |
|
| 2011 |
Berezowska S, Schlegel J. Targeting ErbB Receptors in High-Grade Glioma Current Pharmaceutical Design. 17: 2468-2487. PMID 21827413 DOI: 10.2174/138161211797249233 |
0.375 |
|
| 2011 |
Lee-Sherick AB, Eisenman KM, Sather S, DeRyckere D, Schlegel J, Graham DK. Mer Receptor Tyrosine Kinase Is Over-Expressed In and Contributes to Oncogenesis In Acute Myeloid Leukemia Blood. 118: 1390-1390. DOI: 10.1182/Blood.V118.21.1390.1390 |
0.715 |
|
| Show low-probability matches. |